WO2011046991A3 - Certaines urées substituées comme modulateurs de l'activité de kinases - Google Patents

Certaines urées substituées comme modulateurs de l'activité de kinases Download PDF

Info

Publication number
WO2011046991A3
WO2011046991A3 PCT/US2010/052420 US2010052420W WO2011046991A3 WO 2011046991 A3 WO2011046991 A3 WO 2011046991A3 US 2010052420 W US2010052420 W US 2010052420W WO 2011046991 A3 WO2011046991 A3 WO 2011046991A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutically acceptable
compound
formula
acceptable salt
sample
Prior art date
Application number
PCT/US2010/052420
Other languages
English (en)
Other versions
WO2011046991A2 (fr
Inventor
David R. Brittelli
Original Assignee
Gilead Connecticut, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Connecticut, Inc. filed Critical Gilead Connecticut, Inc.
Publication of WO2011046991A2 publication Critical patent/WO2011046991A2/fr
Publication of WO2011046991A3 publication Critical patent/WO2011046991A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention porte sur au moins un composé de Formule I ou un sel pharmaceutiquement acceptable de celui-ci. La présente invention porte également sur des compositions pharmaceutiques comprenant au moins un composé de Formule I ou un sel pharmaceutiquement acceptable et un ou plusieurs véhicules pharmaceutiquement acceptables choisis parmi les supports, les adjuvants et les excipients. L'invention porte sur des procédés de traitement de patients souffrant de certaines maladies et certains troubles sensibles à la modulation de kinases angiogéniques, qui consistent à administrer à de tels patients une quantité d'au moins un composé de Formule I ou d'un sel pharmaceutiquement acceptable efficace pour réduire les signes ou symptômes de la maladie ou du trouble. Ces maladies comprennent un cancer, dont une néoplasie du sein, le cancer de l'endomètre, le cancer du côlon et l'épithéliuma malpighien spinocellulaire du cou. Les procédés de traitement consistent à administrer au moins un tel composé de Formule I ou un sel pharmaceutiquement acceptable comme unique principe actif ou à administrer au moins un composé de Formule I ou un sel pharmaceutiquement acceptable en association avec un ou plusieurs autres agents thérapeutiques. L'invention porte également sur un procédé permettant de déterminer la présence ou l'absence d'une kinase angiogénique dans un échantillon consistant à mettre en contact l'échantillon avec au moins un composé de Formule I ou un sel pharmaceutiquement acceptable dans des conditions qui permettent la détection d'activité de la kinase angiogénique, détecter un niveau de l'activité de la kinase angiogénique et à partir de celui-ci déterminer la présence ou l'absence de la kinase angiogénique dans l'échantillon.
PCT/US2010/052420 2009-10-15 2010-10-13 Certaines urées substituées comme modulateurs de l'activité de kinases WO2011046991A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25198009P 2009-10-15 2009-10-15
US61/251,980 2009-10-15

Publications (2)

Publication Number Publication Date
WO2011046991A2 WO2011046991A2 (fr) 2011-04-21
WO2011046991A3 true WO2011046991A3 (fr) 2011-08-18

Family

ID=43876837

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/052420 WO2011046991A2 (fr) 2009-10-15 2010-10-13 Certaines urées substituées comme modulateurs de l'activité de kinases

Country Status (1)

Country Link
WO (1) WO2011046991A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103214479A (zh) * 2012-01-18 2013-07-24 武汉东宇生物医药科技有限公司 吡唑类萘脲类酪氨酸激酶抑制剂及其应用
EP2626073A1 (fr) * 2012-02-13 2013-08-14 Harmonic Pharma Composé destiné à être utilisé dans la prévention et/ou le traitement d'une maladie neurodégénérative ou d'une maladie impliquant une activation de phosphodiesterase-4 (PDE4)
CN103524421B (zh) * 2013-09-29 2015-04-01 镇江蓝德特药业科技有限公司 新型萘脲类衍生物及其医疗应用
WO2015051149A1 (fr) * 2013-10-04 2015-04-09 The Trustees Of Columbia University In The City Of New York Analogues de sorafenib et leurs utilisations
CN104788366A (zh) * 2014-01-21 2015-07-22 王若文 Raf激酶抑制剂五氟化硫基芳基脲及其制备方法和应用
CA3034332A1 (fr) * 2016-08-17 2018-02-22 Ichan School Of Medicine At Mount Sinai Composes inhibiteurs de kinase, compositions et methodes de traitement du cancer
CN108117551B (zh) * 2016-11-29 2020-03-27 华东理工大学 取代(1H-吡唑[3,4-b]吡啶)脲类化合物及其抗肿瘤用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002065838A1 (fr) * 2001-02-20 2002-08-29 Reckitt Benckiser Inc Procede et compositions de desinfection de surfaces dures
WO2003074005A2 (fr) * 2002-03-01 2003-09-12 Dyax Corp. Peptides liant des recepteurs kdr et vegf/kdr et leurs utilisations en diagnostic et therapie
WO2007005027A1 (fr) * 2005-07-01 2007-01-11 Cell Signaling Technology, Inc. Identification des tumeurs du cancer bronchopulmonaire 'non a petites cellules'' (nsclc) exprimant pdgfr-alpha
US20070232627A1 (en) * 2005-12-21 2007-10-04 Betebenner David A Anti-viral compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002065838A1 (fr) * 2001-02-20 2002-08-29 Reckitt Benckiser Inc Procede et compositions de desinfection de surfaces dures
WO2003074005A2 (fr) * 2002-03-01 2003-09-12 Dyax Corp. Peptides liant des recepteurs kdr et vegf/kdr et leurs utilisations en diagnostic et therapie
WO2007005027A1 (fr) * 2005-07-01 2007-01-11 Cell Signaling Technology, Inc. Identification des tumeurs du cancer bronchopulmonaire 'non a petites cellules'' (nsclc) exprimant pdgfr-alpha
US20070232627A1 (en) * 2005-12-21 2007-10-04 Betebenner David A Anti-viral compounds

Also Published As

Publication number Publication date
WO2011046991A2 (fr) 2011-04-21

Similar Documents

Publication Publication Date Title
WO2005019220A3 (fr) Imidazo[1,2-a]pyrazines substituees utilisees comme modulateurs de l'activite d'une kinase
WO2007024294A3 (fr) Certains urees substitues, modulateurs de l'activite des kinases
WO2011046991A3 (fr) Certaines urées substituées comme modulateurs de l'activité de kinases
TW200639165A (en) Certain substituted ureas as modulators of kinase activity
MX350010B (es) Inhibidores syk de imidazopiridinas.
EP2331095A4 (fr) Certains inhibiteurs de kynurénine-3-monooxygénase, compositions pharmaceutiques, et procédés d'utilisation de ceux-ci
PH12017502049A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
MX2014001088A (es) Ciertos inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas, y metodos de uso de las mismas.
WO2011014255A8 (fr) Traitement de la maladie de crohn au moyen de laquinimod
EA201490279A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
BR112012018500A2 (pt) alguns inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de uso destas
WO2009039397A3 (fr) Amides substitués, procédé pour les préparer et procédé pour les utiliser
MX2015005798A (es) Terapia de combinacion.
WO2007136518A3 (fr) Traitement de troubles auto-immunitaires
WO2014205555A8 (fr) Procédés et utilisations pour diagnostiquer et traiter le cancer de la prostate
HK1120409A1 (en) Treatment of diseases by subcutaneous administration of a vegf antagonist
EA201590655A1 (ru) Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений
UA107578C2 (uk) Комбінована терапія при лікуванні діабету
EA201491460A1 (ru) ПРИМЕНЕНИЕ ЛАХИНИМОДА В ЛЕЧЕНИИ ПАЦИЕНТОВ С БОЛЕЗНЬЮ КРОНА, У КОТОРЫХ НЕ ЭФФЕКТИВНА ТЕРАПИЯ ПЕРВОЙ ЛИНИИ АНТИ-TNFα
NZ703940A (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
EA200971053A1 (ru) Способы лечения кожных язв
MA33922B1 (fr) Dérivés hétéroaromatiques de phénylimidazole en tant qu'inhibiteurs de l'enzyme pde10a
MX2014011946A (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodos de uso de los mismos.
GB2496800A (en) Combination pharmaceutical composition and methods of treating diseases or conditions associated with respiratory disease or condition
MX2011013775A (es) Un metodo para el tratamiento, alivio de sitomas de, mitigacion, mejoramieto y prevencion de una enfermedad, desorden o condicion cognoscitiva.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10823984

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10823984

Country of ref document: EP

Kind code of ref document: A2